Metagenomi Therapeutics (MGX) Revenue (2023 - 2026)

Metagenomi Therapeutics (MGX) has 4 years of Revenue data on file, last reported at $1.2 million in Q1 2026.

• Revenue for Q1 2026 came in at $1.2 million, down 69.76% year-over-year; the trailing twelve-month figure through Mar 2026 was $22.3 million (down 50.66% YoY), and the FY2025 annual result was $25.2 million, down 51.79% from the prior year.
• Revenue slipped to $1.2 million in Q1 2026 per MGX's latest filing, from $3.9 million in the prior quarter.
• Over five years, Revenue peaked at $20.0 million in Q2 2024 and troughed at $1.2 million in Q1 2026.
• A 4-year average of $9.5 million and a median of $9.6 million in 2024 frame the typical range for Revenue.
• The sharpest annual moves came in 2024 and 2026: Revenue soared 76.48% in 2024, then slumped 69.76% in 2026.
• A 4-year view of Revenue shows it stood at $12.4 million in 2023, then fell by 22.46% to $9.6 million in 2024, then slumped by 59.32% to $3.9 million in 2025, then slumped by 68.09% to $1.2 million in 2026.
• Business Quant data shows MGX's Revenue at $1.2 million in Q1 2026, $3.9 million in Q4 2025, and $8.7 million in Q3 2025.